


## Endoscopic Application of Ankaferd Blood Stopper as a Novel Experimental Treatment Modality for Upper Gastrointestinal Bleeding: A Case Report\*

TO THE EDITOR: Ankaferd is a unique medicinal plant extract, which has historically been used in Turkish traditional medicine as a hemostatic agent (1). Ankaferd Blood Stopper ([ABS] Ankaferd Health Products Ltd., Istanbul, Turkey) as a medicinal product has been approved in the management of external hemorrhage and dental surgery bleedings in Turkey based on the safety and efficacy reports indicating its sterility and nontoxicity ([www.ankaferd.com](http://www.ankaferd.com)). Ankaferd comprises a standardized mixture of the plants *Thymus vulgaris*, *Glycyrrhiza glabra*, *Vitis vinifera*, *Alpinia officinarum* and *Urtica dioica*. The basic mechanism of action for Ankaferd is the formation of an encapsulated protein network that provides focal points for vital erythrocyte ag-

gregation. Ankaferd-induced protein network formation with blood cells, particularly erythrocytes, covers the primary and secondary hemostatic system without disturbing individual coagulation factors (1).


A 52-yr-old man had undergone Whipple's resection with the diagnosis of stage IIB (T2N1M0) distal cholangiocarcinoma in December 2006 at our hospital. He subsequently received six cycles of chemotherapy. He was then lost to follow-up until January 2008, when he admitted to the emergency room with severe upper gastrointestinal bleeding that required the transfusion of 6 units of erythrocyte suspension. He underwent upper gastrointestinal endoscopy (January 25, 2008) which showed an afferent loop with blood and with adherent clot on an ulcerated stoma at the site of hepatico-jejunostomy anastomosis (HJA). Endoscopic intervention was performed with epinephrine injection and argon plasma coagulation. However, these interventions failed to achieve optimal bleeding control. Follow-up hemoglobin levels continued to drop from 11.4 to 9.0 g/dL within 6 days (Fig. 1). A repeated upper endoscopy (January 31, 2008)



Abbreviations: E: Epinephrine, APC: Argon Plasma Coagulation, UES: unit of Erythrocyte Suspension, ABS: Ankaferd blood stopper

**Figure 1.** Hemoglobin levels of the patient during the clinical follow-up and managements including the topical use of Ankaferd via the endoscopic intervention of ABS.

\*American Medical Journal'da (Gastronterol 2008;2156-215) yayinlandi.



**Figure 2.** Upper panel (A): Actively bleeding afferent loop with red blood and ulcerated stoma of hepaticojejunoanastomosis in the patient with operated distal cholangiocarcinoma. Lower panel (B): The topical use of Ankaferd via the endoscopic intervention completely controlled the bleeding within seconds.

showed signs of recent bleeding with the presence of dark clots and coffee-ground blood distal to the gastrojejunostomy anastomosis, with no active bleeding from the ulcerated stoma of the HJA. With a suspicion of local recurrence, multiple biopsies were obtained. Anticipating bleeding, informed consent regarding the experimental nature of ABS as means of attaining hemostasis was obtained prior to the procedure. To control the bleeding from the biopsy site, 15 mL of ABS were applied topically, which produced

immediate results. (Fig. 2 upper (A) and lower (B) panels). Follow-up hemoglobin levels are depicted in Figure 1. There were no findings consistent with malignancy, and an upper endoscopy performed on February 2, 2008 did not reveal any stigmata of bleeding, after which the patient was discharged.

Hemoclips, injection therapy and thermocoagulation are the most commonly used types of endoscopic hemostasis for the control of gastrointestinal bleeding, but still there are the problems of rebleeding, the need for surgery, and mortality

## 2158 Letters to the Editor

(2). Bleeding due to peptic ulcer (3) and gastric varices (4) are also important especially in “poor outcome” patients (5). The effective management of the bleeding problem is particularly evident in patients with hereditary and acquired hemorrhagic diathesis including neoplasia and the use of anticoagulant, antihemostatic drugs (6, 7).

The present observation regarding the hemostatic effects of the topical use of ABS in a case with upper GI bleeding opens the way for the design of future case-controlled clinical trials in a distinct setting of gastrointestinal bleeding. Ankaferd-induced formation of the protein network covers the entire physiological hemostatic process without affecting any particular clotting factor (1). ABS may, therefore, be effective both in individuals with normal hemostatic parameters as well as in patients with deficient primary and/or secondary hemostasis.

*Mevlut Kurt, M.D.<sup>1</sup>*

*Selcuk Disibeyaz, M.D.<sup>1</sup>*

*Meral Akdogan, M.D.<sup>1</sup>*

*Nurgul Sasmaz, M.D.<sup>1</sup>*

*Salih Aksu, M.D.<sup>2</sup>*

*İbrahim Celalettin Haznedaroglu, M.D.<sup>2</sup>*

<sup>1</sup>*Department of Gastroenterology*

*Turkiye Yuksek Ihtisas Hospital*

*Ankara, Turkey and*

<sup>2</sup>*Department of Hematology*

*Hacettepe University Medical Faculty*

*Ankara, Turkey*

## REFERENCES

1. Goker H, Haznedaroglu IC, Ercetin S, et al. Haemostatic actions of the folkloric medicinal plant extract, Ankaferd blood stopper. *J Int Med Res* 2008;36:163–70.
2. Sung JJ, Tsoi KK, Lai LH, et al. Endoscopic clipping versus injection and thermo-coagulation in the treatment of non-variceal upper gastrointestinal bleeding: A meta-analysis. *Gut* 2007;56:1364–73.
3. Cho YK, Kim CS, Kim SY, et al. The hemostatic effect of endoscopic sodium hyaluronate injection in peptic ulcer bleeding. *Hepatogastroenterology* 2007;54:1276–9.
4. Javvaji S, Kumar A, Madan K, et al. Management of gastric variceal bleeding. *Trop Gastroenterol* 2007;28:51–7.
5. Imperiale TF, Dominitz JA, Provenzale DT, et al. Predicting poor outcome from acute upper gastrointestinal hemorrhage. *Arch Intern Med* 2007;167:1291–6.
6. Kadayifci A, Haznedaroglu IC, Savas MC. Risk of withdrawing chronic anticoagulation without antithrombotic prophylaxis. *Am J Gastroenterol* 1997;92:361–2.
7. Soyly AR, Buyukasik Y, Cetiner D, et al. Overt gastrointestinal bleeding in haematologic neoplasms. *Dig Liver Dis* 2005;37:917–22.